GRAIL, Inc. GRAL
We are an innovative commercial-stage healthcare company focused on shifting the paradigm in early cancer detection at population scale. 10-K, Item 1
- Headquarters
- Sunnyvale, CA
- CEO
- Joshua J. Ofman
- Next results
- around Jan 11, 2027
GRAL among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
44 new risk paragraphs. 10-K filed Mar 12, 2026 against Mar 5, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
9 checks on the latest 10-K. Checks, not verdicts.
0facts worth reading about all 9 checks found nothing to note
-
Receivables -9.9% ($20.3M to $18.3M) vs revenue +17.2% ($125.6M to $147.2M), -27.1 pts apart
-
Cash from operations −$299.0M vs net income −$408.4M (FY ending Dec 31, 2025)
-
Same auditor in both 10-Ks: Ernst & Young LLP
6 more checks with nothing to note
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
44 paragraphs in Risk Factors that were not in the 10-K filed Mar 5, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Mar 5, 2025 10-K, ITEM 1A
Our NHS-Galleri Trial did not meet its stated primary endpoint, which may adversely affect our business, stock price, and ability to obtain regulatory approvals, coverage and reimbursement, or achieve commercial adoption. In February 2026, we announced topline results from our NHS-Galleri Trial, which enrolled approximately 140,000…
-
Item 1A · new paragraph · not in the 10-K filed Mar 5, 2025 10-K, ITEM 1A
For example, in February 2026, we announced topline results from the NHS-Galleri Trial, which did not achieve its primary endpoint of statistically significant combined Stage 3 and 4 cancer reduction. Not meeting the stated primary endpoint may lead healthcare providers, payors, regulators, and the investment community to question the…
-
Item 1A · new paragraph · not in the 10-K filed Mar 5, 2025 10-K, ITEM 1A
Our clinical trials to date have been conducted on an earlier version of Galleri. We have in the past improved, and intend in the future to improve, our products to enhance performance, offerings, scalability, and/or cost of sales, including through the launches of new versions. However, we may not be successful in transitioning our…
-
Item 1A · new paragraph · not in the 10-K filed Mar 5, 2025 10-K, ITEM 1A
In February 2026, the Nancy Gardner Sewell Medicare MCED Coverage Act became law and created a Medicare coverage benefit category for multi-cancer early detection tests. The law included certain standards, including that CMS would establish coverage through a national coverage determination (“NCD”) process under “reasonable and…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $55.5M | $93.1M | $125.6M | $147.2M |
| Net income | −$5.4B | −$1.5B | −$2.0B | −$408.4M |
| Operating cash flow | −$561.3M | −$595.8M | −$577.2M | −$299.0M |
| Free cash flow | −$584.2M | −$608.7M | −$582.4M | −$299.9M |
Revenue, FY2022 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$147.2M ▲ 17.2% in FY2025−$408.4M in FY2025−$299.9M in FY2025
Recent filings
2 filings in the last 30 days · SEC EDGAR
-
10-QNov 5, 2026Quarterly report (10-Q) period ended Sep 30, 2026
-
8-KNov 4, 2026Quarterly results 8-K item 2.02
About the company
GRAIL, Inc., Sunnyvale, CA · from the 10-K filed Mar 12, 2026
We are an innovative commercial-stage healthcare company focused on shifting the paradigm in early cancer detection at population scale. We believe screening individuals for many types of cancer with a single test represents a significant opportunity to reduce the global burden of cancer. Our multi-cancer early detection test (“Galleri”) can screen for many types of cancer, accurately predicting the specific organ or tissue type where the cancer signal originated (the “Cancer Signal of Origin”, or “CSO”), with high positive predictive values (“PPV”) and low false positive rates, all from a simple blood draw.
- Headquarters
- Sunnyvale, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 4, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Mar 12, 2026 (open at SEC), compared with the 10-K filed Mar 5, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GRAL/export.csv") into a cell.